key: cord-0978870-vi3evve6 authors: Pascarella, Stefano; Bianchi, Martina; Giovanetti, Marta; Narzi, Daniele; Cauda, Roberto; Cassone, Antonio; Ciccozzi, Massimo title: The SARS‐CoV‐2 Mu variant should not be left aside: It warrants attention for its immuno‐escaping ability date: 2022-02-28 journal: J Med Virol DOI: 10.1002/jmv.27663 sha: bdce1e0369359714b27a6b0dc0c22e9bdb776335 doc_id: 978870 cord_uid: vi3evve6 The COVID‐19 pandemic continues to have a threatening impact on a global scale, largely due to the emergence of newly SARS‐CoV‐2 variants. The Mu (PANGO lineage B.1.621), was first identified in Colombia in January 2021 and was classified as a variant of interest (VOI) in August 2021, due to a constellation of mutations that likely‐mediate an unexpectedly enhanced immune resistance to inactivated vaccine‐elicited antibodies. Despite recent studies suggesting that the Mu variant appears to have less infectivity than the Delta variant, here we examined the structural effect of the Mu spike protein mutations and predicted the potential impact on infectivity of the Mu variant compared with the Delta and Delta plus spike protein. Due to these important epidemiological properties, the Mu variant is now responsible for 39% and 13% of infections in Colombia and Ecuador, respectively. Subsequently, in September 2021, the Mu variant has been detected in more than 20 countries. 1 Mutations arise as a natural by-product of viral replication. RNA viruses typically have higher mutation rates than DNA viruses. Coronaviruses, however, make fewer mutations than most RNA viruses because they encode an enzyme that corrects some of the errors made during replication. In most cases, the fate of a newly arising mutation is determined by natural selection. Those that confer a competitive advantage with respect to viral replication, transmission, or escape from immunity will increase in frequency, and those that reduce viral fitness tend to be culled from the population of circulating viruses. However, mutations can also increase and decrease in frequency due to chance events. There are currently very few studies looking into the Mu variant. As research on this specific variant is still at a preliminary stage, it is too early to conclude whether the strain is more transmissible or more severe than other variants. However, the spike protein mutations seem to facilitate viral entry of the Mu variant into ACE2expressing cells. We examined the structural effect of the Mu spike protein mutations and predicted the potential impact on infectivity of the Mu variant compared with the Delta and Delta plus spike protein. In fact, some scientists have warned that the Mu strain could become a threat if it were to become the dominant variant. This is due to its ability to spread more easily through cells in the human body, something that is also seen in the Delta variant. As a matter of fact, at the time this manuscript is being written, the new omicron variant seems to be a candidate to become one of the worldwide dominant variants. Nonetheless, studying the structural properties of the Spike Mu variant can provide a general and deeper understanding of the evolution of the SARS-CoV-2 and of the relationships between virus protein structure, infectivity, and interaction with the immune system (as in the case of lambda variant 2 ). Spike variant sequences were retrieved from the GISAID translated protein data set. The reference Wuhan Spike sequence is labeled by the RefSeq code yp_009724390. Representative isolates of the Spike sequences of the Mu, Delta, and Delta plus variants are identified by the GISAID codes EPI_ISL_2178393, EPI_ISL_1634920, and GenBank UEN64961, respectively. Variant spike RBD-ACE2 and antibody complexes have been modeled by in-silico mutagenesis using the ad hoc tools in PyMOL. 3 Energy minimization protocol embedded in the molecular graphics program Swiss-PdbViewer 4 has been applied to remove residue steric overlaps at the interface. The protocol used the GROMOS96 43B1 force field, cutoff 10 Å, and 100 steps of steepest descent minimization followed by 1000 steps of conjugate gradients in vacuo. The minimization was stopped if the energy difference between two consecutive steps was lower than 0.05 kJ/mol. Only residues at the interface have been minimized. This forcefield does not include the parameters to describe glycans which were therefore ignored during minimization. However, the glycans present in the RBD and NTD structures are apparently far from the complex interface and do have not the potential to interfere with it. The noncovalent interactions taking place at the interface of the predicted complexes were identified with the RING 2.0 web server. 5 The server provides a fast tool to detect intra and interchain interactions including solvent and ions. Protein structural analysis and visualization have been carried out with PyMOL. 6 Sequence alignment and visualization relied on MAFFT 7 and Jalview, 8 respectively. Computational alanine scanning of the interface residues of the Spike complexes was carried out through the webserver DrugScore PPI . 9 The server provides a fast and accurate tool to predict the binding free energy changes upon alanine mutations at protein-protein interfaces using a knowledge-based scoring function. Molecular dynamics was applied to study the complex RBD-ACE2. The starting structure of the reference form of the spike RBD bound to ACE2 was taken from the Protein Data Bank (PDB code: 6M0J), while the structures of the Mu, Delta, and Delta plus variants were modeled starting from the reference form as described above. Protonation states of titratable protein residues were determined based on empirical pKa prediction performed with the PropKa program. The position of the proton on the neutral histidine residues was set by visual inspection of the structure. The systems were solvated in a dodecahedron box, imposing a minimum distance of 1.6 nm between the protein and the box, using the TIP3p water model. Na + and Cl − ions were added to the systems at a concentration of 150 mM with an excess of Na + ions to compensate for the net negative charge of the solute. Protein residues were described by the Amber03 force field. The simulated systems were composed of about 230 000 atoms each. Long-range electrostatic interactions were treated using the particle mesh Ewald (PME) method, with a short-range cutoff of 1.2 nm and a grid spacing of 0.12 nm. The bond lengths of the hydrogen atoms were constrained to a constant value applying the LINCS algorithm. The temperature was kept constant at 310 K using the Nose-Hoover algorithm with a coupling time constant τ T = 0.4 ps. The system was coupled to a pressure bath at 1 bar with τ P = 1.0 ps, using the Parrinello-Rahman barostat. A time step of 2 fs was used for numerical integration of the equations of motion. All equilibrium MD simulations were preceded by energy minimization using the steepest descent algorithm followed by 20 ns of MD simulation at constant volume and temperature (310 K) with harmonic position restraints (force constant 1000 kJ mol −1 nm −2 ) applied on the heavy atoms of the protein residues present in the original X-ray structure. Finally, unrestrained MD simulations were carried out for 130 ns for each system. MD simulations were carried out using the GROMACS software package. RBD-ACE2 binding energies were estimated as the sum of the short-ranged Lennard-Jones (LJ) interactions and short-range Coulomb interactions between the two groups consisting of the spike RBD and the ACE2 domain as implemented in the function energygrps of the Gromacs package. Binding energies were calculated averaging over 100 ns of unrestrained MD simulations (i.e., neglecting the first 30 ns of each simulation). Interactions occurring at the RBD-ACE2 interfaces in Wuhan and Mu, Delta, and Delta plus variants were compared. RING 2.0 analysis predicts that mutations characterizing the RBD of the variants alter the interaction patterns. Mu mutation at site 501 of RBD adds a π-π stacking interaction between ACE2 Y41 and RBD Y501 ( Figure 1A ). The Y501 also interacts with ACE2 K353 through a Van der Waals contact (Table 1) . Increased interaction stability induced by the presence of interface Y501 was already described. 10 Mutations in the Delta variant do not directly involve interface interactions; however, it has been suggested that the increased positive surface electrostatic potential induced by the replacing basic residues may stabilize interaction with the negatively charged ACE2 surface. 11, 12 A similar effect on the electrostatic surface potential can be induced by the Mu mutation E484K. The Delta plus variant possesses one more mutation with respect to the parent Delta, namely K417N (Table 1) . Apparently, this mutation removes a salt bridge that in the reference Spike connects K417 and ACE2 D30 ( Figure 1B ). The contribution of the residues to the stability of the RBD-ACE2 interface has been predicted with the application of DrugScore PPI in-silico alanine scanning. Results are reported in Table 1 Table 2 . Considering the total RDB-ACE2 interaction energy, given by the sum of the Coulomb and LJ contributions, the lowest value was found for the reference system. (Table 1 ). Effect of Mu, Delta, and Delta plus mutations on RBD interaction with neutralizing antibodies has been considered in two study cases: interaction with the antibodies COVA2-04 and COVA2-39 corresponding to the complexes reported in the PDB coordinate sets 7JMO and 7JMP, respectively. 13 The two antibodies, coded by the gene IGHV3-53, differ from each other mainly for the length of the CDR H3 In the interaction with COVA2-04 (reported in the PDB structure 7JMO), the Mu RBD mutation Y501 may form an additional H-bond interaction with the antibody residue S29 of the Light chain CDR L1. This observation has been corroborated by the DrugScore PPI in-silico alanine scanning that assigns to Y501 a higher ΔΔG than that of the corresponding reference residue (Table 3) . Moreover, the mutation E484K may create a local patch of positive surface electrostatic potential complementary to a negatively charged region in COVA2-04 ( Figure S2 ). Overall, these results suggest that Mu RBD can bind this antibody with a higher affinity. The Delta variant RBD displays an interaction pattern with COVA2-04 similar to that of the reference Spike. However, it has been suggested that the mutations occurring in the RBD may increase the positive surface potential that can influence interaction with the negative patches of the antibody ( Figure S2 ). The K417N mutation that characterizes the Delta plus RBD, removes the reference salt bridge formed between K417 and E97 of the antibody CDR H3 and Y52 of CDR H2. DrugScore PPI confirms that the energy contribution of N417 to the stability of the complex is about half with respect to K417 in the reference RBD (Table 3) . Overall, these results suggest a possible decrease of the affinity for the antibody. Interaction to antibody COVA2-39 (PDB code 7JMP) displays a similar pattern in the case of reference, Delta, and Delta plus variants. In fact, the antibody interacts with the RBD regions not affected by mutations. On the contrary, the mutation E484K on the Mu RBD induces disruption of the hydrogen bond between the carboxylic group of E484 and the NH of the peptide bond of G54 of antibody CDR H2. In this case, also, DrugScore PPI is not able to detect any significant variation of the contribution of residue 484 to the interface stability. The most evident effect of the E484K mutation is on the electrostatic potential surface that becomes more positive ( Figure S2 ). Effect of the Mu, Delta, and Delta plus mutations on NTD interaction with antibodies has also been modeled in two study cases: NTD-4A8 and NTD-5-7 corresponding to the PDB codes 7C2L and 7RW2, respectively. The NTD of Delta and Delta plus variants has been modeled onto the templates of the reference NTDs contained in the selected PDB complexes because of the presence of the deletion of the positions 157-158 ( Figure S1 ). The Mu NTD has been created by in-silico mutagenesis starting from the reference structures of the selected complexes. Mutations occurring within Mu, Delta, and Delta plus NTDs do not change the residue charge and, as a consequence, modification of the electrostatic surface potential is not expected to be relevant for the interaction with the antibodies (Figure 2 ). Interface interactions in the complexes with 4A8 antibody (PDB 7C2L) display the same pattern between the reference, Delta, and Delta plus NTDs. Indeed, the interacting interfaces are free from mutations. On the contrary, the Mu Y145N mutation in NTD removes of the Van der Waal interaction with antibodies A101, V102, and Y111 located in the CDR H3 (Figure 3 ). This observation suggests that removal of interfacial atomic contacts may decrease affinity between these two proteins. Details are reported in Table 3 . DrugScore PPI in-silico alanine scanning supports these considerations: contribution to the interface interaction energy is predicted to be 0.01 and 1.98 kcal/mol for N and Y145, respectively. Mu, Delta, and Delta plus mutations do not appear to significantly influence the interaction to 5-7 antibody. In this case, also, mutations do not alter the NTD interface to the antibody (results not shown). Over the course of the severe acute respiratory syndrome coronavirus 2 pandemic, the clinical, scientific, and public health communities have had to respond to new viral genetic variants. Each one has triggered a flurry of media attention, a range of reactions from the scientific community, and calls from governments to either "stay calm" or pursue immediate countermeasures. While many scientists were initially skeptical about the significance of the D614G alteration, the emergence of the new "UK variant" (lineage B.1.1.7) has raised widespread concern. Understanding which variants are concerning, and why, requires an appreciation of virus evolution and the genomic epidemiology of SARS-CoV-2. Mu was first identified in Colombia in January 2021, and outbreaks have since been "sporadically reported" in South Characterization of the emerging B.1.621 variant of interest of SARS-CoV-2 Shortening epitopes to survive: the case of Sars-Cov-2 Lambda variant The {PyMOL} molecular graphics system: version~1 SWISS-MODEL: homology modelling of protein structures and complexes The RING 2.0 web server for high quality residue interaction networks Schrodinger LLC The AxPyMOL molecular graphics plugin for Microsoft PowerPoint: version 1:8 MAFFT multiple sequence alignment software version 7: improvements in performance and usability Jalview version 2-a multiple sequence alignment editor and analysis workbench DrugScorePPI webserver: fast and accurate in silico alanine scanning for scoring protein-protein interactions Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies SARS-CoV-2 B.1.617 Indian variants: are electrostatic potential changes responsible for a higher transmission rate Structural Dynamics of SARS-CoV-2 variants: a health monitoring strategy for anticipating Covid-19 outbreaks An alternative binding mode of IGHV3-53 antibodies to the SARS-CoV-2 receptor binding domain Emerging SARS-CoV-2 B.1.621/Mu variant is prominently resistant to inactivated vaccine-elicited antibodies A cluster of the new SARS-CoV-2 B.1.621 lineage in Italy and sensitivity of the viral isolate to the BNT162b2 vaccine Neutralization of the SARS-CoV-2 Mu variant by convalescent and vaccine serum Rapid genome sequencing in hospitals to identify potential vaccine-escape SARS-CoV-2 variants SARS-CoV-2 Variants and considerations of inferring causality on disease severity The SARS-CoV-2 Mu variant should not be left aside: It warrants attention for its immuno-escaping ability The authors declare no conflict of interest.